Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study of L-Annamycin Treatment for Patients with Previously Treated Metastatic Soft Tissue Sarcoma

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This study focuses on patients with metastatic soft-tissue sarcomas, a type of cancer that develops in soft tissues and has spread to other parts of the body. The research evaluates a medication called Liposomal Annamycin, which belongs to a group of drugs known as anthracyclines that are used to treat various types of cancer. The medication is given through intravenous administration (directly into a vein).

The purpose of this research is to test how well patients tolerate Liposomal Annamycin when given weekly and to determine how effective it is in treating metastatic soft-tissue sarcomas. The study is divided into two parts: the first part focuses on finding the right dose that can be safely given to patients, while the second part examines how well the treatment works.

The study involves patients who have already received previous treatment for their cancer, including prior therapy with anthracycline medications. During the study, participants will receive Liposomal Annamycin treatment, and their response to the medication will be monitored through regular medical examinations and imaging tests. The treatment will continue as long as patients show benefit from it and do not experience unacceptable side effects.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial qualification

    You must be 18 years or older with confirmed soft-tissue sarcoma and metastases

    Your physical condition will be evaluated using the ECOG scale (a measure of your ability to perform daily activities)

    Your life expectancy should be greater than three months

    You must have at least one measurable tumor larger than 10 millimeters

  2. Step 2

    Medical history verification

    You must have previously received anthracycline therapy (a type of cancer medication)

    For phase II trial participants: maximum of three previous treatment courses are allowed

    At least two weeks must have passed since your last treatment

    Any side effects from previous treatments must have improved to mild level or returned to your normal state within four weeks

  3. Step 3

    Laboratory tests

    Blood tests will check your:

    - White blood cell count (neutrophils ≥ 1500/mL)

    - Platelet count (≥100,000/mL)

    - Hemoglobin levels (≥8.0 g/dL)

    - Kidney function

    - Liver function

  4. Step 4

    Treatment administration

    You will receive Liposomal Annamycin through an intravenous infusion (into your vein)

    The medication will be given on a weekly schedule

    Regular monitoring will assess how your body responds to the treatment

  5. Step 5

    Ongoing monitoring

    Your tumor size will be measured regularly using imaging tests

    Your overall health status will be monitored throughout the study

    The study will continue until December 31, 2025

  6. Step 6

    Safety requirements

    You must use effective contraception methods during the study and for six months after completing treatment

    Women must use two forms of contraception (such as intrauterine device, oral contraceptive, or double barrier device)

    Men and their partners must also use effective contraception methods during this period

Who can join the trial?

13 criteria

  • Must be 18 years or older when signing the consent form
  • Must have an ECOG performance status of 2 or less (meaning able to perform most daily activities) and life expectancy greater than 3 months
  • Must have confirmed soft tissue sarcoma (a type of cancer that develops in soft tissues) with spread to other parts of body (metastases) that cannot be cured with surgery
  • Must have at least one measurable tumor that is larger than 10 millimeters
  • Must have previously received anthracycline therapy (a type of chemotherapy) and shown disease progression
  • Must have completed previous treatments at least 2 weeks before starting the study, with side effects resolved
  • Must have adequate blood test results, including:
    • Sufficient white blood cells and platelets
    • Hemoglobin level of 8.0 g/dL or higher
    • Good kidney function
    • Normal or near-normal liver function tests
    • Must be able to understand and sign the consent form and follow study requirements
    • Must agree to use effective birth control methods during the study and for 6 months after:
      • Women must use two forms of contraception
      • Men and their partners must use effective contraception

Who cannot join the trial?

13 criteria

  • History of allergic reactions or severe sensitivity to similar drugs or their components
  • Presence of brain metastases (cancer that has spread to the brain) unless treated and stable for at least 4 weeks
  • Heart problems, including: - Heart failure - Irregular heartbeat - Heart attack within the last 6 months
  • Severe liver problems or abnormal liver function tests
  • Kidney problems requiring dialysis
  • Active, uncontrolled infections requiring treatment
  • Other types of cancer within the last 3 years (except for adequately treated non-melanoma skin cancer or cervical cancer)
  • Blood disorders that significantly affect blood cell counts
  • Participation in other clinical trials within 4 weeks before starting this study
  • Pregnancy or breastfeeding
  • Inability or unwillingness to use effective birth control methods during the study
  • Any condition that, in the opinion of the study doctor, would make participation unsafe
  • Unable to understand or sign the informed consent form
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

L-Annamycin (Liposomal Annamycin) is a medication being studied for treating soft tissue sarcomas that have spread to other parts of the body. It is a chemotherapy drug that has been modified with a special coating (liposomal) to help it work better in the body. This medication is designed to fight cancer cells in patients who have already received previous treatment for their sarcoma. The liposomal formulation may help reduce some side effects while maintaining the medication's effectiveness against cancer cells.

What is already known about the treatment

L-Annamycin - A liposomal formulation of annamycin, administered intravenously as a weekly treatment for patients with metastatic soft-tissue sarcomas (STS). This investigational chemotherapy agent is currently being studied in clinical trials for patients who have failed at least one prior systemic therapy. The medication belongs to the anthracycline class of chemotherapy drugs, and its mechanism of action involves interfering with DNA replication in cancer cells through its liposomal delivery system, which is designed to enhance drug delivery while potentially reducing cardiac toxicity commonly associated with traditional anthracyclines. The formulation's liposomal encapsulation aims to improve the drug's distribution to tumor sites and minimize exposure to healthy tissues.

Investigated diseases

  • Soft Tissue Sarcoma

    A group of cancers that develop in the body's soft tissues, including muscles, tendons, fat, blood vessels, nerves, and deep skin tissues. This cancer can occur anywhere in the body, though it most commonly starts in the arms, legs, or abdomen. Soft tissue sarcomas typically begin as a painless lump that grows over time. When the disease spreads (metastasizes), it commonly travels to the lungs, though it can also spread to other organs. The cancer cells can break away from the original tumor and travel through the bloodstream or lymphatic system to form new tumors in other parts of the body.

  • Metastatic Soft Tissue Sarcoma

    An advanced stage of soft tissue sarcoma where cancer cells have spread from their original location to other parts of the body. The metastatic process occurs when cancer cells break away from the primary tumor and travel through blood vessels or lymph nodes to establish new tumors in distant locations. In this stage, tumors can be found in multiple areas of the body simultaneously. The disease typically maintains similar characteristics to the original tumor but now affects multiple sites.

Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase ITrial ID2024-517678-12-00Protocol codeANNA-SARCEstimated enrolment30 patientsSponsorNarodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).